The success of personalized medicine in oncology relies on using highly effective and
precise therapeutic modalities such as small interfering RNA (siRNA) and monoclonal …

Despite substantial advances in targeting mutant KRAS, tumor resistance to KRAS inhibitors
(KRASi) remains a major barrier to progress. Here, we report proteostasis reprogramming as …

Summary KRAS G12C inhibitors (adagrasib and sotorasib) have shown clinical promise in
targeting KRAS G12C-mutated lung cancers; however, most patients eventually develop …

In this commentary, we advance the notion that mutant KRAS (mKRAS) is an ideal tumor
neoantigen that is amenable for targeting by the adaptive immune system. Recent progress …

Drug combinations are key to circumvent resistance mechanisms compromising response to
single anti-cancer targeted therapies. The implementation of combinatorial approaches …

Lung adenocarcinoma (LUAD), commonly driven by KRAS mutations, is responsible for 7%
of all cancer mortality. The first allele-specific KRAS inhibitors were recently approved in …

Simple Summary Cancer is caused by changes in DNA called mutations that alter the way
proteins work. We know that RAS proteins are one of the most commonly mutated proteins in …

Pancreatic ductal adenocarcinoma (PDAC) is one of the deadliest human malignancies.
Advanced PDAC is considered incurable. Nearly 90% of pancreatic cancers are caused by …

Abstract KRAS G12C mutations in non-small cell lung cancer (NSCLC) partially respond to
KRAS G12C covalent inhibitors. However, early adaptive resistance occurs due to rewiring …

Abstract The Kirsten Rat Sarcoma Virus (KRAS) oncoprotein, one of the most prevalent
mutations in cancer, has been deemed undruggable for decades. The hypothesis of this …